| 产品名称： | 重组小鼠白细胞介素-22 |
|---|---|
| 产品又名： | Iltifa细胞因子, Iltifa细胞因子 |
| 英文名称： | Interleukin-22; IL-22; IL-10-Related T-Cell-Derived-Inducible Factor; IL-TIF; IL-TIF Alpha; Interleukin-22a; IL-22a; Il22; Il22a; Iltif; Iltifa |
| 产品说明: | 重组小鼠白细胞介素-22(IL-22)由大肠杆菌表达系统产生，编码Leu34-Val179的目的基因得到表达。 |
| 背景说明: | 白细胞介素-22(IL-22)在小鼠T细胞和肥大细胞中被初步鉴定为IL-9诱导的基因。小鼠IL-22 cDNA编码179个氨基酸残基蛋白，其中33个氨基酸信号肽被切割，生成147个氨基酸成熟蛋白，其序列与人白细胞介素22和白细胞介素10的同源性分别为79%和22%。IL 22已被证明能激活肝癌细胞株中的STAT-1和STAT-3，并上调急性时相蛋白的产生。IL-22是正常小鼠T细胞在Con A活化后产生的.注射脂多糖还可诱导小鼠各器官中IL-22的表达，提示IL-22可能参与了炎症反应。功能性IL-22受体复合物由两个受体亚基组成，即IL-22R(以前称为CRF 2-9的孤儿受体)和IL-10 Rβ(以前称为CRF 2-4)，属于Ⅱ类细胞因子受体家族。 |
| 级别： | AR |
| 品牌： | ELITE-MEDIA |
| 产品目录号： | Q9JJY9 |
| 产品规格： | 10ug、50ug |
| 产品外观： | 乳白色均一粉末。 |
| 制剂： | 冻干从0.2μm过滤液20 mm PB，150 mm NaCl，pH7.0。 |
| 保存条件： |
冻干蛋白应保存在<-20°C，室温下保存3周。
重组蛋白溶液可在4-7℃保存2~7d。
重组样品在<-20℃温度下稳定3个月。
|
| 质量控制: |
纯度：通过减少SDS-PAGE而确定的95%以上。
生物活性：以其诱导人大肠腺癌细胞分泌IL-10的能力为指标.
内毒素：LAL法测定小于0.1ng/g(1 Eu/？g)。
|
| 注意事项： | 避免呼入和皮肤接触。 |
| 文献引用： |
Extract from indigo naturalis and a process for preparing the same Lin Yin-ku, et al. (Galderma S.A. patent:10251926 43564)
Pharmaceutical composition comprising refined indigo naturalis extract and the use thereof Chantalat Laurent, et al. (Galderma S.A. patent:10232006 43543)
Interleukin-22 Attenuated Renal Tubular Injury in Aristolochic Acid Nephropathy via Suppressing Activation of NLRP3 Inflammasome Shaofei Wang, et al. (frontiers in Immunology, 2019)
PHARMACEUTICAL COMPOSITION COMPRISING REFINED INDIGO NATURALIS EXTRACTS AND THE USE THEREOF Chantalat Laurent, et al. (Galderma S.A. patent:US20190160128 2019)
EXTRACT FROM INDIGO NATURALIS AND A PROCESS FOR PREPARING THE SAME Lin Yin-ku, et al. (Galderma S.A. patent:US20190224264 2019)
EXTRACT FROM INDIGO NATURALIS AND A PROCESS FOR PREPARING THE SAME Lin Yin-ku, et al. (Galderma S.A. patent:US20180099020 2018)
Extract from indigo naturalis and a process for preparing the same Lin Yin-ku, et al. (Galderma S.A. patent:9861673 2018)
Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation Shaofei Wang, et al. (Cell Death&Disease, 2017)
EXTRACT FROM INDIGO NATURALIS AND A PROCESS FOR PREPARING THE SAME Lin Yin-ku, et al. (Galderma S.A. patent:US20170266248 2017)
PHARMACEUTICAL COMPOSITION AND THE USE THEREOF Chantalat Laurent, et al. (Galderma S.A. patent:US20170304381 2017)
Latest Publication
IL-22 ameliorated cardiomyocyte apoptosis in cardiac ischemia/reperfusion injury by blocking mitochondrial membrane potential decrease, inhibiting ROS and cytochrome C. Che, Tian, Chen, Xia, Liu, Su, Biochim Biophys Acta Mol Basis Dis(2021 Sep 01)
Dynamic alterations and durability of T helper 22 and its corresponding cytokines following treatment in pediatric visceral leishmaniasis. Kalani, Choopanizadeh, Pourabbas, Pouladfar, Asaee, Ghanbary Ghalati, Moravej, Cytokine(2021 Aug)
Changes in liver steatosis in HIV-positive women are associated with the BMI, but not with biomarkers. Fernandez-Botran, Plankey, Ware, Bordon, Cytokine(2021 Aug)
Specific bioactivity of IL-22 in intestinal cells as revealed by the expression of IL-22RA1 in Mandarin fish, Siniperca chuatsi. Huo, Chen, Laghari, Li, Hou, Gan, Huang, Li, Nie, Dev Comp Immunol(2021 Aug)
Gut Bacteria Induce Granzyme B Expression in Human Colonic ILC3s In Vitro in an IL-15-Dependent Manner. Castleman, Dillon, Thompson, Santiago, McCarter, Barker, Wilson, J Immunol(2021 Jun 11)
|
买家导航
Iltifa细胞因子产品基本信息
Iltifa细胞因子产品说明书pdf版和相关资料下载
Iltifa细胞因子产品应用举例
- 上一篇：IL-31细胞因子
- 下一篇：IL-23R细胞因子
